XRCC1 is a key component of DNA base excision repair, single strand break repair and backup non-homologous end joining pathway. XRCC1 deficiency promotes genomic instability, increases cancer risk and may have clinical application in breast cancer. We investigated XRCC1 expression in early breast cancers (n=1297) and validated in an independent cohort of ER-α negative breast cancers (n= 281). Preclinically, we evaluated XRCC1 deficient and proficient Chinese hamster and Human cancer cells for synthetic lethality application using double strand break (DSB) repair inhibitors [KU55933 (ATM inhibitor) and NU7441 (DNA-PKcs inhibitor)]. In breast cancer, loss of XRCC1 (16%) was associated with high grade (p<0.0001), loss of hormone receptors (p<0.0001), triple negative (p<0.0001) and basal like phenotypes (p=0.001). Loss of XRCC1 was associated with a 2-fold increase in risk of death (p<0.0001) and independently with poor outcome (p<0.0001). Pre-clinically, KU55933 and NU7441 were synthetically lethal in XRCC1 deficient compared to proficient cells as evidenced by hypersensitivity to DSB repair inhibitors, accumulation of DNA double strand breaks, G2/M cell cycle arrest and induction of apoptosis. This is the first study to demonstrate that XRCC1 deficiency in breast cancer results in an aggressive phenotype and that XRCC1 deficiency could also be exploited for a novel synthetic lethality application using DSB repair inhibitors.
INTRODUCTION
Impaired DNA repair is a driving force for carcinogenesis and may promote aggressive clinical behaviour in breast cancer (1, 2). Base excision repair (BER) is required for the accurate removal of damaged DNA bases induced by oxidising and alkylating agents. DNA single strand breaks induced by chemotherapeutics are processed by single strand break repair (SSBR), a pathway related to BER. XRCC1 (X-ray repair cross-complementing gene 1) is a critical factor in BER, SSBR and back-up non-homologous end joining pathway (B-NHEJ). XRCC1, a 70-kDa protein, has three functional domains: an N-terminal DNA binding domain, a centrally-located BRCT I domain and a C-terminal BRCT II domain. Although XRCC1 has no known enzymatic activity [reviewed in (3, 4) ], it functions as a molecular scaffold protein and is intimately involved in the coordination of DNA repair by interacting with several components of BER/SSBR pathway such as DNA glycosylases, apurinic/apyrimidinic endonulcease (APE1), PARP-1, polynulceotide kinase (PNK) and ligase III [reviewed in (3, 4) ].
Pre-clinically, XRCC1 deficiency delays SSB rejoining, induces mutations and results in elevated levels of sister chromatid exchanges, a hallmark of genomic instability.
XRCC1 deficiency results in hypersensitivity to ionizing radiation and chemotherapeutics (4, 5) . In human association studies, germline polymorphisms in XRCC1 may influence cancer risk (6) (7) (8) (9) , and also response to radiotherapy (10, 11) and chemotherapy (12) in patients (13, 14) .
Given the essential role of XRCC1 in DNA repair and carcinogenesis, we hypothesised that XRCC1 may be dysregulated in breast cancer. In the current study we provide the first evidence that XRCC1 deficiency in tumours is an independent predictor of poor clinical outcome and is associated with an aggressive phenotype.
Moreover we also provide the first preclinical evidence that XRCC1 deficiency in cancer can be exploited for synthetic lethality application using DNA double strand break repair inhibitors. Our study has important clinical translational applications in patients.
METHODS

STUDY PATIENTS
The study was performed in a consecutive series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series. All patients were treated uniformly in a single institution and have been investigated in a wide range of biomarker studies (15) (16) (17) . Supplemental Table S1 summarizes patient demographics. Supplemental treatment data 1 summarizes various adjuvant treatments received by patients in this cohort.
We also evaluated an independent series of 281 ER-α negative invasive BCs diagnosed and managed at the Nottingham University Hospitals between 1999 and 2007. All patients were primarily treated with surgery, followed by radiotherapy and anthracycline chemotherapy. The characteristics of this cohort are summarised in supplementary Table S2 .
The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al (18) , were followed throughout this study.
This work was approved by Nottingham Research Ethics Committee.
Tissue Microarrays (TMAs) and immunohistochemistry (IHC)
Tumours were arrayed in tissue microarrays (TMAs) constructed with 2 replicate 0.6mm cores from the centre and periphery of the tumours. The TMAs were immunohistochemically profiled for XRCC1 and other biological antibodies (Supplementary-Table S3 ) as previously described (19) (20) (21) (22) . Immunohistochemical staining for XRCC1 was performed using the Bond Max automated staining machine To validate the use of TMAs for immunophenotyping, full-face sections of 40 cases were stained and protein expression levels of the different antibodies were compared. The concordance between TMAs and full-face sections was excellent (k = 0.8). Positive and negative (by omission of the primary antibody and IgG-matched serum) controls were included in each run.
Evaluation of immune staining
The tumour cores were evaluated by three specialist pathologists blinded to the clinicopathological characteristics of patients, in two different settings. There was excellent intra and inter-observer agreements (k > 0.8; Cohen's κ and multi-rater κ tests, respectively). Whole field inspection of the core was scored and intensities of nuclear staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage of each category was estimated (0-100%). H-score (range 0-300) was calculated by multiplying intensity of staining and percentage staining as previously described (19) (20) (21) (22) . Low/negative XRCC1 (XRCC1-) expression was defined by mean of H-score of ≤100.
Not all cores within the TMA were suitable for IHC analysis due to missing cores or absence of tumour cells.
Statistical analysis
Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL). Where appropriate, Pearson's Chi-square, Fisher's exact, Student's t and ANOVA one way tests were used. Cumulative survival probabilities were estimated using the KaplanMeier method, and differences between survival rates were tested for significance using the log-rank test. Multivariate analysis for survival was performed using the Cox proportional hazard model. The proportional hazards assumption was tested using standard log-log plots. Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable. All tests were two-sided with a 95% CI and a p value < 0.05 considered significant. For multiple comparisons, p values were adjusted according to Holm-Bonferroni correction method (24) .
Sample size and power analysis
Power of study, sample size and effect size were determined using PASS (NCSS, version 11, USA). Cox regression of the log hazard ratio on XRCC1 covariant (27) . MCF-7 cells were plated in 6-well plates (2 ml medium/well without antibiotics). At 50% confluence, transfection was achieved using Lipofectamine TM Data was analysed using FlowJo7.6.1 software.
Western blot analysis:
This assay was performed as described previously (28). 
PRECLINICAL SYNTHETIC LETHALITY EVALUATION
The clinical data confirms that XRCC1 loss is an independent poor prognostic marker. As XRCC1 deficient cells are BER/SSBR deficient and reliant on DSB repair pathways for maintaining genomic stability, we hypothesized that XRCC1 deficient cells are likely to be hypersensitive to DSB repair inhibitors and could be exploited for synthetic lethality applications. Ataxia telangectasia mutated (ATM) is critical for DNA DSB sensing and signal transduction (29) . DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is an essential component of non-homologous endjoining (NHEJ) (30) . We therefore investigated highly specific DSB repair small molecule inhibitors for synthetic lethality. 
DISCUSSION:
XRCC1 is a key scaffolding protein intimately involved in BER, SSBR and B-NHEJ. This is the first study to evaluate XRCC1 protein expression in breast cancer.
Survival analyses confirmed that XRCC1 negativity is an independent predictor of poor clinical outcome. We validated our data in an independent cohort of ER negative tumours and confirmed the negative prognostic significance. In triple negative tumours, XRCC1 negativity remains significantly associated with poor clinical outcome compared to XRCC1 positive tumours. XRCC1 may be a useful tool in the stratification of BC patients for adjuvant therapy. Our data suggests that otherwise low risk (NPI <3.4) XRCC1 negative tumours should be included within high risk groups and would benefit from adjuvant systemic therapy. Moreover, poor clinical outcome with loss of XRCC1 expression was also confirmed in high risk BC (NPI≥ 3.4), suggesting that alternative aggressive systemic chemotherapy may be warranted in this group. However, one limitation of this study is that these historical patients received CMF chemotherapy, and whether XRCC1 expression can stratify patients who receive a more modern anthracycline/taxol based chemotherapy remains to be established in follow-on studies.
Our clinical data is in contrast to preclinical studies wherein XRCC1 deficient cell lines have been shown to be sensitive to cytotoxic therapy (3, 4) . Mutator phenotype is a well-recognised phenomenon where DNA repair deficiency leads to genomic instability which further leads to increased accumulation of mutations and selection of aggressive malignant clones that may be resistant to therapy (2, 34) . DNA polymerase beta, another key factor in DNA base excision repair, has been shown to exhibit the mutator phenotype phenomenon (2, 34) . We speculate that loss of CAN-12-2929 pathways to maintain cellular survival, we hypothesised that XRCC1 deficiency in somatic tumours could be exploited for synthetic lethality application by blocking the DSB repair pathway in cells. Ataxia telengectasia mutated (ATM) and DNAdependent protein kinase catalytic subunit (DNA-PKcs) are members of the phosphatidylinositol-3-kinase-like protein kinase (PIKK) family. ATM is a key sensor and transducer of DNA damage signalling during homologous recombination (HR) in response to DSBs generated during replication (29) . DNA-PKcs is an essential component of non-homologous end-joining (NHEJ) (30) . Whereas NHEJ operates throughout the cell cycle, HR is limited to S and G2. However, the mechanisms by which cells choose between NHEJ and HR remains to be established. In addition, the molecular complexities of interactions between DNA-PKcs, ATM, NHEJ and HR are only beginning to emerge (39) . For example, it appears that there may be more than 40 phophorylation sites in DNA-PKcs and how post translational modifications of DNA-PKcs impact HR is unknown (39) . Moreover, novel interactions between XRCC1, ATM and DNA-PKcs have also been recently reported (40, 41) . ATM-Chk2-dependent phosphorylation of XRCC1 was been shown to promote BER by Chou et al. (40) . In another study, DNA-PKcs was shown to phosphorylate BRCT1 domain of XRCC1 at serine 371 and cause XRCC1 dimer dissociation. In addition, XRCC1 was also shown to stimulate phosphorylation of p53-Ser 15 by DNA-PKcs in that study (41) . XRCC1 is also a key component of the backup NHEJ pathway (42, 43) . 
We demonstrate herein that highly specific and potent ATM and DNA-PKcs inhibitors are synthetically lethal in XRCC1 deficient cells. We have concluded synthetic lethality for the following reasons. Firstly, in Chinese Hamster (CH) cells deficient in In conclusion, we provide the first clinical evidence that XRCC1 deficiency is an independent poor prognostic biomarker in breast cancer patients. Pre-clinically we have demonstrated that XRCC1 deficiency can be exploited for synthetic lethality application in breast cancer by blocking DSB repair using ATM or DNA-PKcs inhibitors. Accelerated pharmaceutical development of DSB repair inhibitors is urgently warranted to expand synthetic lethality strategies in breast cancer. 
